BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 29579619)

  • 1. Epigenetic small molecule modulators of histone and DNA methylation.
    Hauser AT; Robaa D; Jung M
    Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation.
    Liu K; Liu Y; Lau JL; Min J
    Pharmacol Ther; 2015 Jul; 151():121-40. PubMed ID: 25857453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of histone demethylases in cancer therapy.
    Hoffmann I; Roatsch M; Schmitt ML; Carlino L; Pippel M; Sippl W; Jung M
    Mol Oncol; 2012 Dec; 6(6):683-703. PubMed ID: 22902149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.
    Eglen RM; Reisine T
    J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential.
    Bayo J; Dalvi MP; Martinez ED
    Future Med Chem; 2015; 7(16):2243-61. PubMed ID: 26510529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
    Verma SK; Knight SD
    Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Regulatory Mechanisms Induced by Resveratrol.
    Fernandes GFS; Silva GDB; Pavan AR; Chiba DE; Chin CM; Dos Santos JL
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29104258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting histone lysine methylation in cancer.
    McGrath J; Trojer P
    Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.
    Castillo-Aguilera O; Depreux P; Halby L; Arimondo PB; Goossens L
    Biomolecules; 2017 Jan; 7(1):. PubMed ID: 28067760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Histone Methylation in Cancer.
    McCabe MT; Mohammad HP; Barbash O; Kruger RG
    Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in histone methyltransferases and histone demethylases].
    Wang X; Zhu WG
    Ai Zheng; 2008 Oct; 27(10):1018-25. PubMed ID: 18851779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting components of epigenome by small molecules.
    You JS; Han JH
    Arch Pharm Res; 2014 Nov; 37(11):1367-74. PubMed ID: 25070764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic drugs that do not target enzyme activity.
    Owen DR; Trzupek JD
    Drug Discov Today Technol; 2014 Jun; 12():e29-34. PubMed ID: 25027371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging epigenetic targets and therapies in cancer medicine.
    Popovic R; Licht JD
    Cancer Discov; 2012 May; 2(5):405-13. PubMed ID: 22588878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
    Tsai CT; So CW
    Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promises and challenges of anticancer drugs that target the epigenome.
    Verbrugge I; Johnstone RW; Bots M
    Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.